PMID- 28895206
OWN - NLM
STAT- MEDLINE
DCOM- 20180703
LR  - 20210904
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Print)
IS  - 0902-4441 (Linking)
VI  - 99
IP  - 6
DP  - 2017 Dec
TI  - Inpatient vs outpatient autologous hematopoietic stem cell transplantation for 
      multiple myeloma.
PG  - 532-535
LID - 10.1111/ejh.12970 [doi]
AB  - BACKGROUND: High-dose chemotherapy and autologous hematopoietic stem cell 
      transplantation (auto-HCT) are commonly performed for multiple myeloma (MM) 
      patients and may be as safe in the outpatient setting as in the inpatient 
      setting. METHODS: We performed a single-center retrospective analysis of all MM 
      patients undergoing auto-HCT between January 2008 and December 2012. We 
      categorized patients as outpatient vs inpatient auto-HCT and compared clinical 
      characteristics and outcomes between the groups. RESULTS: One thousand and 
      forty-six patients were included (669 inpatients, 377 outpatients). Patients 
      transplanted as outpatients were significantly younger (58 [34-78] vs 62 [31-82], 
      P < .001) and more likely to have an hematopoietic stem cell comorbidity index 
      (HCT-CI) score <2 (P = .003) and creatinine <2 (P < .001). There were no 
      differences in treatment-related mortality (TRM) but the inpatient group 
      experienced significantly more grade 2-5 (P = .003) and grade 3-5 (P = .003) 
      adverse events (AEs). 2 year progression-free survival (PFS) was significantly 
      longer in the outpatient group (60% vs 50%, HR =HR 0.7, 95% CI 0.6-0.9, 
      P = .005). 2 year OS was also longer in the outpatient group (83% vs 77%, HR 0.6, 
      95% CI 04-0.9, P = .01). CONCLUSION: Outpatient auto-HCT can be safely performed 
      for selected patients with MM. Differences in outcomes are likely related to 
      baseline clinical characteristics rather than choice of treatment setting.
CI  - (c) 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Shah, Nina
AU  - Shah N
AUID- ORCID: 0000-0002-1971-8173
AD  - Department of Medicine, Hematology-Oncology, University of California San 
      Francisco, San Francisco, CA, USA.
FAU - Cornelison, A Megan
AU  - Cornelison AM
AD  - Department of Stem Cell Transplantation and Cellular Therapy, University of Texas 
      M.D. Anderson Cancer Center, Houston, TX, USA.
FAU - Saliba, Rima
AU  - Saliba R
AD  - Department of Stem Cell Transplantation and Cellular Therapy, University of Texas 
      M.D. Anderson Cancer Center, Houston, TX, USA.
FAU - Ahmed, Sairah
AU  - Ahmed S
AD  - Department of Stem Cell Transplantation and Cellular Therapy, University of Texas 
      M.D. Anderson Cancer Center, Houston, TX, USA.
FAU - Nieto, Yago L
AU  - Nieto YL
AD  - Department of Stem Cell Transplantation and Cellular Therapy, University of Texas 
      M.D. Anderson Cancer Center, Houston, TX, USA.
FAU - Bashir, Qaiser
AU  - Bashir Q
AD  - Department of Stem Cell Transplantation and Cellular Therapy, University of Texas 
      M.D. Anderson Cancer Center, Houston, TX, USA.
FAU - Parmar, Simrit
AU  - Parmar S
AD  - Department of Stem Cell Transplantation and Cellular Therapy, University of Texas 
      M.D. Anderson Cancer Center, Houston, TX, USA.
FAU - Hosing, Chitra
AU  - Hosing C
AD  - Department of Stem Cell Transplantation and Cellular Therapy, University of Texas 
      M.D. Anderson Cancer Center, Houston, TX, USA.
FAU - Popat, Uday
AU  - Popat U
AD  - Department of Stem Cell Transplantation and Cellular Therapy, University of Texas 
      M.D. Anderson Cancer Center, Houston, TX, USA.
FAU - Shpall, Elizabeth J
AU  - Shpall EJ
AD  - Department of Stem Cell Transplantation and Cellular Therapy, University of Texas 
      M.D. Anderson Cancer Center, Houston, TX, USA.
FAU - Champlin, Richard E
AU  - Champlin RE
AD  - Department of Stem Cell Transplantation and Cellular Therapy, University of Texas 
      M.D. Anderson Cancer Center, Houston, TX, USA.
FAU - Qazilbash, Muzaffar
AU  - Qazilbash M
AD  - Department of Stem Cell Transplantation and Cellular Therapy, University of Texas 
      M.D. Anderson Cancer Center, Houston, TX, USA.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171008
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cohort Studies
MH  - Female
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects/methods
MH  - Humans
MH  - *Inpatients
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/diagnosis/*epidemiology/mortality/*therapy
MH  - *Outpatients
MH  - Survival Analysis
MH  - Transplantation, Autologous
MH  - Treatment Outcome
PMC - PMC8415170
MID - NIHMS1736047
OTO - NOTNLM
OT  - multiple myeloma
OT  - outpatient
OT  - stem cell transplantation
EDAT- 2017/09/13 06:00
MHDA- 2018/07/04 06:00
PMCR- 2021/09/03
CRDT- 2017/09/13 06:00
PHST- 2017/09/07 00:00 [accepted]
PHST- 2017/09/13 06:00 [pubmed]
PHST- 2018/07/04 06:00 [medline]
PHST- 2017/09/13 06:00 [entrez]
PHST- 2021/09/03 00:00 [pmc-release]
AID - 10.1111/ejh.12970 [doi]
PST - ppublish
SO  - Eur J Haematol. 2017 Dec;99(6):532-535. doi: 10.1111/ejh.12970. Epub 2017 Oct 8.